



US007094401B1

(12) **United States Patent**  
**Worman et al.**

(10) **Patent No.:** **US 7,094,401 B1**  
(45) **Date of Patent:** **Aug. 22, 2006**

(54) **HCV CORE PROTEIN BINDING AGENTS FOR TREATMENT OF HEPATITIS C VIRUS INFECTION**

(75) Inventors: **Howard J. Worman**, New York, NY (US); **Naoto Mamiya**, Aichi (JP)

(73) Assignee: **The Trustees of Columbia University in the City of New York**, New York, NY (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/407,432**

(22) Filed: **Sep. 29, 1999**

(51) **Int. Cl.**  
**A61K 38/43** (2006.01)

(52) **U.S. Cl.** ..... **424/94.1**; 424/196.11; 435/5; 435/7.1; 435/183; 435/188; 435/15; 435/193

(58) **Field of Classification Search** ..... 424/159.1, 424/161.1, 94.1, 196.11; 435/5, 7.1, 183, 435/188, 15, 193

See application file for complete search history.

(56) **References Cited**

**OTHER PUBLICATIONS**

Owsianka and Patel, *Virology* 257, 330-340 (1999), May 10, 1999.\*  
 Alter, M.J. (1997) "Epidemiology of Hepatitis C" *Hepatology*, 26:625-655 (Exhibit 2).  
 Chien, C., et al. (1991) "The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest" *Proc. Natl. Acad. Sci. U.S.A.*, 88:9578-9582 (Exhibit 3).  
 Choo, Q.-L., et al. (1989) "Isolation of a cDNA clone derived from blood-borne nonA, nonB viral hepatitis genome" *Science*, 244:359-362 (Exhibit 4).  
 Choo, Q.-L., et al. (1991) "Genetic organization and diversity of the hepatitis C virus" *Proc. Natl. Acad. Sci. U.S.A.*, 88:2451-2455 (Exhibit 5).  
 Chuang, R.-Y., et al. (1997) "Requirement of the DEAD-box protein Dedlp for messenger RNA translation" *Science*, 275:1468-1471 (Exhibit 6).  
 Fields, S., and Song, O. (1989) "A novel genetic system to detect protein-protein interactions" *Nature*, 340:245-246 (Exhibit 7).  
 Fukushi, S., et al. (1997) "The sequence element of the internal to ribosome entry site and a 25-kilodalton cellular protein contribute efficient internal initiation of translation of hepatitis C virus RNA" *J. Virol.*, 71:1662-1666 (Exhibit 8).  
 Gee, S. L., and Conboy, J. G. (1994) "Mouse erythroid cells express multiple putative RNA helicase genes exhibiting high sequence conservation from yeast to mammals" *Gene*, 140:171-177 (Exhibit 9).  
 Hsieh, T.-Y. (1998) "Hepatitis C virus core protein interacts with heterogeneous nuclear ribonucleoprotein K" *J. Biol. Chem.*, 271, 17651-17659 (Exhibit 10).  
 Kato, N., et al. (1990) "Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis" *Proc. Natl. Acad. Sci. U.S.A.*, 87:9524-9528 (Exhibit 11).  
 Kim, J. L., et al. (1998) "Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding" *Structure*, 6:89-100 (Exhibit 12).

Kim, D. W., et al. (1994) "Trans-suppression of gene expression by hepatitis C viral core protein" *Jpn. J. Med. Sci. Biol.*, 47:211-220 (Exhibit 13).

Kuo, G., et al. (1989) "An assay for circulating antibodies to a major etiological virus of human non-A, non-B hepatitis" *Science*, 244:359-363 (Exhibit 14).

Lanford, R. E., et al. (1993) "Analysis of hepatitis C virus capsid, E1, and E2/NS1 proteins expressed in insect cells" *Virology*, 197:225-235 (Exhibit 15).

Leroy, P., et al. (1989) "The protein encoded by a murine male germ cell-specific transcript is a putative ATP-dependent RNA helicase" *Cell*, 57:549-559 (Exhibit 16).

Liang, T. J. (1998) "Combinaton therapy for hepatitis C Infection" *N. Eng. J. Med.*, 339; 1549-1550 (Exhibit 17).

Mamiya, N., et al. (1997) "Epidemiology, prevention, clinical features and therapy of hepatitis B, C, and G" *Current Opinion in Infectious Diseases.*, 10:390-397 (Exhibit 18).

Matsumoto, M., et al. (1996) "Homotypic interactions and multimerization of the hepatitis C virus core protein" *Virology.*, 218:43-51 (Exhibit 19).

Matsumoto, M., et al. (1997) "Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-β receptor" *J. Virol.* 71:1301-1309 (Exhibit 20).

Moradpour, D., Kary, P., rice, C. M., and Blum, H.E. (1998) "Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins" *Hepatology*, 28:192-201 (Exhibit 21).

National Institutes of Health Consensus Development Conference Panel Statement (1997) "Management of Hepatitis C" *Hepatology*, 26:2S-10S (Exhibit 22).

Okamoto, H., et al. (1991) "Nucleotide sequence of the genomic RNA hepatitis C virus isolated from a human carrier: comparison with reported isolates from conserved and divergent regions" *J. Gen. Virol.*, 72:2697-6704 (Exhibit 23).

Ray, R. B., et al. (1996) "Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype" *J. Virol.*, 70:4438-4443 (Exhibit 24).

(Continued)

*Primary Examiner*—Laurie Scheiner

(74) *Attorney, Agent, or Firm*—John P. White, Esq.; Cooper & Dunham LLP

(57) **ABSTRACT**

The present invention provides a method of treating or preventing hepatitis C virus infection in a subject which comprises administering an effective amount of an agent to the subject, wherein the agent is capable of specifically binding to the HCV core protein so as to inhibit hepatitis C virus replication. The present invention also provides a method for determining whether a compound can treat or prevent hepatitis C virus infection in a subject, wherein the compound treats or prevents hepatitis C virus infection by specifically inhibiting the binding of HCV core protein and said agent so as to suppress hepatitis C virus replication. The present invention further provides a composition for inhibiting cell growth, comprises a HCV core protein or a variant thereof, wherein said HCV core protein or its variant inhibit cancer cell growth by inhibiting the cellular DEAD box proteins.

OTHER PUBLICATIONS

Ray, R. B., et al. (1997) "Transcriptional repression of p53 promoter by hepatitis C virus core protein" *J. Biol. Chem.*, 272:10983-10986 (Exhibit 25).

Reynolds, J. E., et al. (1995) "Unique features of internal initiation of hepatitis C virus RNA translation" *EMBO J.*, 14:6010-6020 (Exhibit 26).

Rozen, F., et al. (1990) "Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A and 4F" *Mol. Cell Biol.* 10:1134-1144 (Exhibit 27).

Selby, M. J., et al. (1993) "Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome" *J. Gen. Virol.*, 74:1103-1113 (Exhibit 28).

Suzuki, R., et al. "Nuclear localization of the truncated hepatitis C virus core protein with its hydrophobic C terminus deleted" *J. Gen. Virol.*, 76:53-61 (Exhibit 29).

Takamizawa, A., et al. (1991) "Structure and organization of the hepatitis C genome isolated from human carriers" *J. Virol.*, 65:1105-1113 (Exhibit 30).

Yao, N., et al. (1997) "Structure of the hepatitis C virus RNA helicase domain" *Nat. Struct. Biol.*, 4:63-67 (Exhibit 31).

Ye, Q., and Worman, H. J. (1996) "Interaction between an integral protein of the nuclear envelope inner membrane and human chromodomain proteins homologous to *Drosophila* HP1" *J. Biol. Chem.*, 271:14653-14656 (Exhibit 32).

Zhu, N., et al. (1998) "Hepatitis C virus core protein binds to cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis" *J. Virol.* 72:3691-3697 (Exhibit 33).

\* cited by examiner

FIGURE 1




FIGURE 2

SEQ. ID. NO:1

MSHVAVENALGLDQQFAGLDLNSSDNQSGGSTASKGRYIPPHLRNREATRGFYDKDSSGWSSSKDKDAYSSFGSRSDSRGKSSFFS  
 DRGSGSRGRFDDRRSDYDGGIGSRGDRSGFGKFERGGNSRWCDSDEDDWSKPLPPSERLEOELEFSGGNTGINFEKYDDIPVEATG  
 NNCPPHIESFSDVEMGEIIMGNIELTRYTRPTPVQKHAIPIIKEKRDLMACAQTGSGKTAFLLPILSQIYSDGPGGEALRAMKENG  
 RYGRRKQYPIISLVLAPTRELAVQIYEEARKFSYRSRVRPCVYGGADIGQQIRDLERGCHLLVATPGRLVDMMERGKIGLDFCKYL  
 VLDEADRMLDMGFEQIRRIVEQDTMPKGVRRHTMMFSATFPKEIQMLARDFLDEYIFLAVGRVGSSTSENIQKVVWVEESDKRSF  
 LLDLLNATGKDSLTLVFVETKKGADSLDFLYHEGYACTSIHGDRSQDRREALHQFRSGKSPILVATAVAARGLDISNVKHVINP  
 DLPSDIEEYVHRIGRTGRVGNLGLATSEFFNERNINITKDLLLVEAKOEVPWSWLENMAYEHHYKGSRRGRSKSSRFSGGFGARDY  
RQSSGASSSSFRSSRRSSGGGGHSSRRGFGGGYGGFYNSDGYGGNYSQGVDDWNGN

SEQ. ID. NO:2

GSTSENIQKVVWVEESDKRSFLDLLNATGKDSLTLVFVETKKGADSLDFLYHEGYACTSIHGDRSQDRREALHQFRSGKSPI  
 LVATAVAARGLDISNVKHVINFDLPSPDIEEYVHRIGRTGRVGNLGLATSEFFNERNINITKDLLLVEAKOEVPWSWLENMAYEHHY  
 KGSSRGRSKSSRFSGGFGARDYRQSSGASSSSFRSSRRSSGGGGHSSRRGFGGGYGGFYNSDGYGGNYSQGVDDWNGN

FIGURE 3

SEQ. ID. NO:3

VGSTSENI TQKVVVVEESDKRSFLLDLLNATGKDSLTLVFVETKKGADSLLEDFLYHEGYACTSIHGDRSQRDREREALHQFRSGKSP  
ILVATAVAARGLDISNVKHVINFDLPSDIEEYVHRIGRTGRVGNLGLAT

FIGURE 4

## SEQ. ID. NO:4

1 atggatgac gagggatct ggtgtaccag gcgaagctgg ccgagcagggc tgagcgatac  
 61 gacgaaatgg tggagtcaat gaagaaagta gcagggatgg atgtggagct gacagttgaa  
 121 gaaagaaacc tcctatctgt tgcataataag aatgtgattg gagctagaag agcctcctgg  
 181 agaataatca gcagcattga acagaaagaa gaaaacaagg gaggagaaga caagctaaaa  
 241 atgattcggg aatatcggca aatggttgag actgagctaa agttaatctg ttgtgacatt  
 301 ctggatgtac tggacaaa caaccattcca gcagtaaca ctggcgagtc caaggttttc  
 361 tattataaa tgaaggagg ctaccacagg tatctggcag aatttggcac aggaaacgac  
 421 aggaaggagg ctgctggagaa cagcctagtg gcttataaag ctgctagtga tattgcaatg  
 481 acagaacttc caccaacgca tcctattcgc taggtcttg ctctcaattt ttccgtattc  
 541 tactacgaaa ttcttaattc ccctgaccgt gcctgacggt tggcaaaagc agcttttgat  
 601 gatgcaattg cagaactgga tacgctgagt gaagaaagct ataaggactc tacacttacc  
 661 atgcagttgt tacgtgataa tctgacacta tggacttcag acatgcaggg tgacgggtgaa  
 721 ggcagaata aagaagcgt gcaggacgtg gaagacgaaa atcagtgaga cataagccaa  
 781 caagagaaac ca

## SEQ. ID. NO:5

translation="MDDREDLVYQAKLAEQAERYDEMVESMKKVAGMDVELTVEERNL  
 LSVAYKNVIGARRASWRISSIEQKENGKGGEDKIKMIREYRQMVETELKLIICCDILD  
 VLDKHLIPAANTGESKVFYKMKGDYHRYLAEFATGNDRKEAAENSLVAYKAASDIAM  
 TELPPTHPIRLGLALNFSVFYIEILNSPDRACRLAKAAFDDAIAELDTLSEESYKDS  
 LIMQLLRDNLTLWTSMDQGDGEEQNKEALQDVEDENQ"

FIGURE 5A





FIGURE 5B




HCV Core Protein-DBX Interaction

1 MSHVAVENALGLDQQFAGLDLNSNDNQSGGSTASKGRYIPPHLRNRRAIKCFYDXDSSCMSSSKDKDAYSSFGSRSDSRG  
 DBX 1 MSHVAEEDDELGLDQFAGLDLTSRDQSOGGSTASKGRYIPPHLRNRRAKAFYDXDGSRW...SKDKDAYSSFGSRSDSRG  
 PL10 1 .....MAELSEVONLSINDNNG.....VPPHLR.....GPRSRARNNSNYNNNN...GYNCGRG  
 Ded1p 1  
 81 KSSFFSDR.CSGSRGRFDGRSDYDGI GSRGDRSGFGKFERGGN..SRWCDKSDDEDDWSKPLPFSERLEQELFSGGNTG  
 DBX 81 KSSFFSDRGGSGSRGRFDEGRSDYESYSGSGRSGRSGFGKFERGGN..SRWCDKADDEDDWSKPLPFSERLEQELFSGGNTG  
 PL10 79 GGSFFSN...NRRGCGNGCGFFGNGGSSNSGRSGRWIDCKHVZAPRNEKAEIAIFGVPEDENFQ.....SSC  
 Ded1p 53  
 158 INFEKYDDIPVEATGNCPPIHESFSDVEMGELIMGNIELTRYTRPIVQKHAIPIIKEKRDLMACAQTGSGKTAFAFLLP  
 DBX 158 INFEKYDDIPVEATGNCPPIHESFSDVEMGELIMGNIELTRYTRPIVQKHAIPIIKEKRDLMACAQTGSGKTAFAFLLP  
 PL10 157 INFEKYDDIPVEATGNCPPIHESFSDVEMGELIMGNIELTRYTRPIVQKHAIPIIKEKRDLMACAQTGSGKTAFAFLLP  
 Ded1p 120 INFDNNYDDIPVDLSECKDVPEPIEFESPPPLDGEFFENIKLARITKRPVOKYSPVYANGRDLMACAQTGSGKTCGCFLLP  
 238 ILSQIYSDGPGEALRAMKENGVGRKQYPISLVLAPTRELAVQIYEARKFSYRSRVRPCVVYGGADIGQOIRDLERGC  
 DBX 238 ILSQIYSDGPGEALRAMKENGVGRKQYPISLVLAPTRELAVQIYEARKFSYRSRVRPCVVYGGADIGQOIRDLERGC  
 PL10 237 ILSQIYSDGPGEALRAMKENGVGRKQYPISLVLAPTRELAVQIYEARKFSYRSRVRPCVVYGGADIGQOIRDLERGC  
 Ded1p 200 VLSESEKIGPS...QPESQCSFYQRKAYPFAVIMAPTRIALQIIEDEAKKFTYRSVTKACVVYGGSPIGNQEFERHERGC  
 318 HLLVATPGRVDMMERGKIGLDFCKYLVLEADRMMDMGFEPIRRIIVEQDTMPKQVRRHTMFSATFPKEIQMLARDFL  
 DBX 318 HLLVATPGRVDMMERGKIGLDFCKYLVLEADRMMDMGFEPIRRIIVEQDTMPKQVRRHTMFSATFPKEIQMLARDFL  
 PL10 317 HLLVATPGRVDMMERGKIGLDFCKYLVLEADRMMDMGFEPIRRIIVEQDTMPKQVRRHTMFSATFPKEIQMLARDFL  
 Ded1p 277 DLLVATPGRVDMMERGKISLANVKYLVLEADRMMDMGFEPIRRIIVEQDTMPKQVRRHTMFSATFPKEIQMLARDFL  
 398 DEYIFLAVGRVCGSTSENIQKVVVVEEADKRSFLDLLLNATGKDSLIVVEYTKKADSLIEDFLYHEGYACTSHGDRSQ  
 DBX 398 DEYIFLAVGRVCGSTSENIQKVVVVEEADKRSFLDLLLNATGKDSLIVVEYTKKADSLIEDFLYHEGYACTSHGDRSQ  
 PL10 397 DEYIFLAVGRVCGSTSENIQKVVVVEEADKRSFLDLLLNATGKDSLIVVEYTKKADSLIEDFLYHEGYACTSHGDRSQ  
 Ded1p 357 SDYIFLAVGRVCGSTSENIQKVVVVEEADKRSFLDLLLNATGKDSLIVVEYTKKADSLIEDFLYHEGYACTSHGDRSQ  
 478 RDREALHQFRSGKSPILVATAVAARGLDISNVKHVINFDLPSDIEEVHRIGRTRVGNLGLATSEFNERNINITKDLL  
 DBX 478 RDREALHQFRSGKSPILVATAVAARGLDISNVKHVINFDLPSDIEEVHRIGRTRVGNLGLATSEFNERNINITKDLL  
 PL10 477 RDREALHQFRSGKSPILVATAVAARGLDISNVKHVINFDLPSDIEEVHRIGRTRVGNLGLATSEFNERNINITKDLL  
 Ded1p 436 SERERALFAFRSCAATLAVATAVAARGLDIENVTHVINFDLPSDIEEVHRIGRTRVGNLGLATSEFNENSENIVKGLH  
 558 DLLVEAKQEVPSMLENMAIEHHYKGSRRGRSKSRFSGGFGARDYRQSSGASSSSSSSRASSSRSRSGCGGCHGSRGRGFGGG  
 DBX 558 DLLVEAKQEVPSMLENMAIEHHYKGSRRGRSKSRFSGGFGARDYRQSSGASSSSSSSRASSSRSRSGCGGCHGSRGRGFGGG  
 PL10 557 DLLVEAKQEVPSMLENMAIEHHYKGSRRGRSKSRFSGGFGARDYRQSSGASSSSSSSRASSSRSRSGCGGCHGSRGRGFGGG  
 Ded1p 516 EQLTEANQEVPSLTKDAMMS...AEGRSRSNRGGCFGRNNRDYRQKGCASAGGCGSSRSRSDNSFRGGS.....CGGSD  
 638 GYGFYNSDGYGGINNSQGVDMWGN  
 DBX 638 GYGFYNSDGYGGINNSQGVDMWGN  
 PL10 636 SYGFFYNSDGYGGINNSQGVDMWGN  
 Ded1p 587 S.....KSGCICNSGGSNNSMWM...


FIGURE 6A

FIGURE 6B

**DBX**



**PL10**



**Ded1p**



FIGURE 7A

CORE

DBX




FIGURE 7B




FIGURE 8





FIGURE 9



## HCV CORE PROTEIN BINDING AGENTS FOR TREATMENT OF HEPATITIS C VIRUS INFECTION

Throughout this application, various publications are referenced by author and date. Full citations for these publications may be found listed numerically at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.

### BACKGROUND OF THE INVENTION

Chronic hepatitis C is a major public health problem and one of the leading worldwide causes of chronic liver disease, cirrhosis and hepatocellular carcinoma (1). Approximately 4 million Americans are chronically infected with HCV and as many as 25% of them may eventually develop cirrhosis (2). End-stage liver disease from hepatitis C is now the leading indication for orthotopic liver transplantation in the United States. HCV was identified in 1989 and demonstrated to be the major cause of what was then referred to as non-A, non-B hepatitis (3, 4).

The hepatitis C virus (HCV) is a positive single stranded RNA virus and a member of the Flaviviridae family (3, 6–10). Once hepatitis C virus infects cells, the positive, single-stranded RNA genome is translated into a polyprotein of 3010 to 3033 amino acids, depending upon the strain (6–9). The viral RNA is not capped and translation occurs via internal ribosome entry sites (10, 11). The mechanism of translation from uncapped viral RNA therefore differs from that used by virtually all cellular mRNAs which are capped at their 5' ends.

In hepatocytes, the HCV core protein is mostly localized to endoplasmic reticulum membrane with a large domain facing the cytoplasm (12). It has been shown to form multimers (13). The function of HCV core protein in cells is not clear, however, it may play a role in transformation and oncogenesis (14). Such a function could hypothetically arise as a result of interactions with cellular proteins involved in signal transduction or oncogene or tumor suppressor gene products or by affecting expression from their genes. HCV core protein may also be involved in regulating the immune response as it has been shown to bind to the cytoplasmic domain of lymphotoxin- $\beta$ receptor (15). Some investigators have also shown that a truncated portion of HCV core protein can reach the nucleus (16, 17), suggesting that it may directly affect the expression of cellular genes as demonstrated in vitro (18). It is not clear, however, if this nuclear form is generated in infected cells.

The HCV polyprotein is proteolytically processed by both host cell and viral proteases into several smaller polypeptides (6–9, 12) (FIG. 1). The major structural proteins are a core protein and two envelope proteins (E1 and E2). Four major non-structural proteins called NS2, NS3, NS4, and NS5, are also generated, two of which, NS4 and NS5, are further processed into smaller polypeptides called NS4A, NS4B, NS5A, and NS5B. The non-structural proteins have various enzymatic activities, such as RNA helicase (NS3), protease (NS2, NS3–NS4A complex) and RNA polymerase (NS5B). NS5A has been implicated in determining sensitivity to interferon.

After cells are infected with a virus, viral proteins can interact with host cell proteins and influence cell physiology.

In previous studies, HCV core protein has been shown to bind to lymphotoxin- $\beta$  receptor and other tumor necrosis factor receptor family members (15, 27). A truncated form of HCV core protein also interacts with ribonucleoprotein K in the nucleus (28). We now show that HCV core protein binds to a cellular RNA helicase and, in experimental systems, inhibits capped RNA translation. This provides a novel mechanism by which HCV may inhibit mRNA translation in infected cells or recruit a cellular protein to enhance its own replication.

Despite major advances in diagnosing chronic hepatitis C and screening the blood supply since that time, almost nothing is known about how the virus infects, kills or transforms cells. For this reason, current therapeutic options are limited and new agents have been difficult to develop.

According to a recent National Institutes of Health Consensus Development Conference Panel Statement on the Management of Hepatitis C (5), there is an urgent need for effective antiviral therapeutics capable of inhibiting HCV replication and stopping or delaying the progression of liver disease. The Panel also concluded that a major bottleneck to the drug discovery process is the absence of a readily available cell culture system that is fully permissive for viral replication. A small animal model of HCV infection is also lacking. For these reasons, novel, alternative approaches must be developed to identify targets for the design of therapeutic agents for the treatment of patients with chronic hepatitis C.

The development of specific drugs against HCV has been impeded because there is no non-primate animal model of infection and all attempts to culture the virus have failed. Currently, the only currently approved drugs in the United States are preparations of interferon-alpha and ribavirin. The long-term cure rate of subjects treated with interferon-alpha is less than 10%. The use of ribavirin, in combination with interferon-alpha, has shown slightly better long-term cure, however, still in only a minority of subjects.

### SUMMARY OF THE INVENTION

The present invention provides a method of treating or preventing hepatitis C virus infection in a subject which comprises administering an effective amount of an agent to the subject, wherein the agent is capable of specifically binding to the HCV core protein so as to inhibit hepatitis C virus replication. The present invention provides a method of identifying a compound which can inhibit the functions of hepatitis C virus, wherein said compound inhibits hepatitis C virus replication by inhibiting the interactions between HCV core protein and an agent capable of specifically binding to said HCV core protein, comprising: (a) incubating said compound, the HCV core protein and said agent under a suitable reaction conditions, (b) determining the binding between the HCV core protein and said agent in the presence of said compound, and (c) comparing the binding in step (b) with the binding between the HCV core protein and said agent in the absence of said compound so as to identify a compound which can inhibit the replication of hepatitis C virus by inhibiting the binding between HCV core protein and said agent.

The present invention also provides a method for determining whether a compound can treat or prevent hepatitis C virus infection in a subject, comprising (a) incubating said compound, the HCV core protein and an agent capable of specifically binding to said HCV core protein, (b) determining the binding between the HCV core protein and said agent in the presence of said compound, and (c) comparing the

binding in step (b) with the binding between the HCV core protein and said agent in the absence of said compound so as to identify a compound which can treat or prevent hepatitis C virus infection in a subject, wherein said compound treats or prevents hepatitis C virus infection by specifically inhibiting the binding of HCV core protein and said agent so as to suppress hepatitis C virus replication.

The present invention further provides a composition for inhibiting cell growth, comprises a HCV core protein or a variant thereof, wherein said HCV core protein or its variant inhibit cancer cell growth by inhibiting the cellular DEAD box proteins.

#### BRIEF DESCRIPTION OF THE FIGURES

**FIG. 1:** Diagram of the major processed proteins encoded by the HCV genome. The 3010–3033 amino acid polyprotein is processed into several smaller polypeptides. Core, E1 and E2 are structural polypeptides. Core protein is the virus nucleocapsid and E1 and E2 are viral envelope proteins. The major non-structural proteins are NS2, NS3, NS4 and NS5. NS4 is further processed into NS4A and NS4B and NS5 into NS5A and NS5B. NS2 and part of NS3 are proteases that process the viral polyprotein. NS3 also has RNA-helicase activity. NS4A is a cofactor for the NS3 protease and NS5B is an RNA-dependent, RNA polymerase. The functions of NS4B and NS5A are less-well understood but NS5A is thought to play a role in determining sensitivity to interferon.

**FIG. 2:** Amino acid sequence of human DBX (alternative transcript 2), SEQ ID NO:1. The domain that binds to HCV core protein in the yeast two-hybrid assay is underlined and separately listed as SEQ ID NO:2.

**FIG. 3:** Amino acid sequence of human DBX (alternative transcript 2) from amino acid 509 to amino 645 (SEQ ID NO:3) that binds to HCV core protein in the yeast two hybrid assay.

**FIG. 4:** Complete cDNA sequence of human epsilon 14-3-3 protein (SEQ ID NO:4) and amino acid sequence translation thereof (SEQ ID NO:5).

**FIG. 5:** Binding of DBX to HCV core protein in vitro.

**5A:** A standard amount of <sup>35</sup>S-HCV core protein (amino acids 1–123), 10% of which is shown in the autoradiogram (lane 1), was used in each binding assay. <sup>35</sup>S-HCV core protein was incubated with glutathione-Sepharose (lane 2), 20 μg of GST coupled to glutathione-Sepharose (lane 3) in binding buffer containing 0.15 M NaCl and 0.2 μg of GST-DBX fusion protein coupled to glutathione-Sepharose in buffers containing the NaCl concentrations indicated above each lane (lanes 4–8). Glutathione-Sepharose was then washed with buffer containing the indicated NaCl concentration and the bound proteins were eluted with 4% SDS, subjected to SDS-polyacrylamide gel electrophoresis and detected by autoradiography of dried slabs gels.

**5B:** Binding assay similar to that shown in panel A in which GST-DBX fusion protein was incubated with <sup>35</sup>S-HCV core protein in buffers containing 0.15 M NaCl and 0.05% to 1.0% of Nonidet P-40 (NP-40) (lanes 4–6). Migrations of molecular mass standards are indicated in kilodaltons at the left of each panel.

**FIG. 6:** Primary structures of DBX, PL10 and Ded1 and their interactions with HCV core protein in the yeast two-hybrid assay.

**6A:** Alignment of deduced amino acid sequences of DBX (GenBank Accession number AF000982), PL10 (Gen-

Bank Accession number J04847) and Ded1p (GenBank Accession number X57278) is shown. Identical amino acids are shown as white on black. Conserved substitutions are shown as black on gray. Dots represent gaps to optimize alignments which were obtained using the Pileup program.

**6B:** Two-hybrid assays showing interaction of HCV core protein with DBX and PL10 but not with Ded1p. Yeast strain Y190 was co-transformed with a plasmid expressing the cytoplasmic domain of HCV fused to the GAL4 DNA binding domain and plasmids expressing either a portion of DBX or the corresponding portions of PL10 or Ded1p fused to the GAL4 transcriptional activation domain. Transformants giving β-galactosidase activity (positive interactions) are blue. Control reactions of DBX, PL10 and Dep1p GAL 4 activation domain fusion proteins with GAL4 DNA binding domain alone were negative (data not shown).

**FIG. 7:** Immunofluorescence localization of DBX and HCV core protein in mammalian cells.

**7A:** HeLa cells were transiently transfected with cDNA encoding FLAG-tagged HCV core protein (left panel) or with cDNA encoding myc-tagged DBX (right panel). Cells were incubated with monoclonal anti-FLAG or anti-myc (9E10) antibody followed by rhodamine-conjugated secondary antibody. HCV core protein appears primarily in large, discrete foci at the endoplasmic reticulum membrane whereas DBX has a more diffuse cytoplasmic localization.

**7B:** Co-localization of DBX and HCV core protein in COS-7 cells transiently transfected to express both FLAG-tagged HCV core protein and myc-tagged DBX. All cells were fixed and incubated with the same combination of rabbit anti-FLAG polyclonal antibody and mouse anti-myc monoclonal (9E10) antibody followed by both fluorescein isothiocyanate-conjugated goat anti-rabbit and rhodamine-conjugated goat anti-mouse antibodies. Cells transfected to express FLAG-tagged HCV core protein alone (left column) showed essentially only green fluorescence resulting from anti-FLAG and fluorescein isothiocyanate-conjugated antibody labeling (row G). Cells transfected to express myc-tagged DBX alone (middle column) showed essentially only red fluorescence resulting from anti-myc and rhodamine conjugated antibody labeling (row R). The right column shows COS-7 cells co-transfected to express both FLAG-tagged HCV core protein (row G) and myc-tagged DBX (row R). Merged images (row M) appear yellow where green fluorescence corresponding to HCV core protein localization and red fluorescence corresponding to DBX localization overlap.

**FIG. 8:** Inhibition of DBX and PL10 but not Ded1p by HCV core protein. Yeast strains with chromosomal ded1 deletion complemented with either DBX, PL10, or DED1 cDNAs driven by the yeast GPD promoter on centromeric plasmids were transformed with a plasmid that expressed full-length HCV core protein (top) or control plasmid p423GPD (bottom). The resulting transformants were spread on histidine, leucine drop-out plates and incubated at 30° C. for 7 days and photographs (negatives are shown) were taken of each plate. Note colony growth of all yeast strains transfected with control plasmid (bottom panels). In contrast, DBX- and PL10-complemented ded1-deletion strains do not demonstrate significant colony growth when HCV core protein is expressed whereas growth of the DED1-complemented strain is unaffected (top panels).

FIG. 9: Inhibition of translation of capped mRNA in vitro by HCV core protein. Rabbit reticulocyte lysates were incubated with glutathione-Sepharose beads loaded with either 300 ng of a GST-HCV core fusion protein or GST. In vitro synthesized capped or non-capped luciferase mRNAs were translated at 30° C. for 90 minutes and luciferase activity was measured. Results are expressed as the relative luciferase activities produced in reticulocyte lysates treated equal concentrations of GST-HCV core fusion protein (shaded bars) or GST (open bars, arbitrarily assigned 100% activity). Values shown are means±standard errors (n=6). \*p<0.0001: no significant difference.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a method of treating or preventing hepatitis C virus infection in a subject which comprises administering an effective amount of an agent to the subject, wherein the agent is capable of specifically binding to the HCV core protein so as to inhibit hepatitis C virus replication.

In one embodiment of the method, the agent is capable of specifically binding to the HCV core protein having an amino acid sequence of FIG. 2, SEQ ID NO:1.

As used herein, “inhibition of hepatitis C virus replication” means interrupting or stopping the growth or multiplication of the hepatitis C virus.

In another embodiment of the method, the binding of the agent to hepatitis C virus core protein prevents the hepatitis C virus from attaching to the cells of the subject so as to inhibit hepatitis C virus replication.

In another embodiment of the method, the binding of the agent to hepatitis C virus core protein prevents the hepatitis C virus from entering into the cells of the subject so as to inhibit hepatitis C virus replication.

In another embodiment of the method, the agent binds to the cytoplasmic domain of HCV core protein which comprises amino acid residues 1–123 of said HCV core protein of FIG. 2, SEQ ID NO:1.

In another embodiment of the method, the agent is a polypeptide, a pseudo enzyme, a peptidomimetic compound, a nucleic acid molecule, an antibody or variant thereof.

In another embodiment of the method, the agent comprises a cellular protein.

In another embodiment of the method, the cellular protein comprises a DEAD-box protein, or a 14-3-3 protein.

In another embodiment of the method, the DEAD box protein comprises a DEAD box RNA helicase.

In another embodiment of the method, the DEAD-box RNA helicase is a human DEAD-box protein DBX or a variant thereof.

Variants in amino acid sequence of human DEAD-box protein DBX are produced when one or more amino acids in naturally occurring human DEAD-box protein DBX is substituted with a different natural amino acid, an amino acid derivative, a synthetic amino acid, an amino acid analog or a non-native amino acid. Particularly preferred variants include homologous human DEAD-box protein DBX. Variants of a human DEAD-box protein DBX may include biologically active fragments of naturally occurring human DEAD-box protein DBX, wherein sequences of the variant differ from the wild type human DEAD-box protein DBX sequence by one or more conservative amino acid substitutions. Such substitutions typically would have minimal influence on the secondary structure and hydrophobicity of human DEAD-box protein DBX.

In another embodiment of the method, the human DEAD-box protein DBX has the amino acid sequence of FIG. 2, SEQ ID NO:1.

“Polypeptide” includes both peptides and proteins. “Peptide” means a polypeptide of fewer than 10 amino acid residues in length, and “protein” means a polypeptide of 10 or more amino acid residues in length. In this invention, the polypeptides may be naturally occurring or recombinant (i.e. produced via recombinant DNA technology), and may contain mutations (e.g. point, insertion and deletion mutations) as well as other covalent modifications (e.g. glycosylation and labeling via biotin, streptavidin, fluorocine, and radioisotopes such as <sup>131</sup>I). Moreover, each instant composition may contain more than a single polypeptide, i.e. each may be a monomer (one polypeptide bound to a polymer) or a multimer (two or more polypeptides bound to a polymer or to each other).

As used herein, “effective amount” means an amount of a compound which interrupts the binding between hepatitis C virus core protein and a cellular protein, which can inhibit the hepatitis C virus replication and can be determined using methods well known to those skilled in the art.

In another embodiment of the method, the variant of human DEAD-box protein DBX comprises the amino acid sequence of FIG. 2, SEQ ID NO:2.

In another embodiment of the method, the variant of human DEAD-box protein DBX comprises the amino acid sequence of FIG. 3, SEQ ID NO:3.

In another embodiment of the method, the hepatitis C virus infects the liver of the subject.

In another embodiment of the method, the hepatitis C virus infects the liver of a human.

In another embodiment of the method, the variant of the human DEAD-box protein DBX comprises 100–200 amino acid residues which mimics the amino acid sequence of FIG. 2, SEQ ID NO:2 or the amino acid sequence of FIG. 3, SEQ ID NO: 3.

In another embodiment of the method, the 14-3-3 protein comprises the amino acid sequence of FIG. 4, SEQ ID NO:5 or a variant thereof.

Variants in amino acid sequence of 14-3-3 protein are produced when one or more amino acids in naturally occurring 14-3-3 protein is substituted with a different natural amino acid, an amino acid derivative, a synthetic amino acid, an amino acid analog or a non-native amino acid. Particularly preferred variants include homologous 14-3-3 protein. Variants of a 14-3-3 protein may include biologically active fragments of naturally occurring 14-3-3 protein, wherein sequences of the variant differ from the wild type 14-3-3 protein sequence by one or more conservative amino acid substitutions. Such substitutions typically would have minimal influence on the secondary structure and hydrophobicity of the 14-3-3 protein.

In another embodiment of the method, the variant of said 14-3-3 protein comprises 50–200 amino acid residues which mimics the active site of said 14-3-3 protein of FIG. 4, SEQ ID NO:5.

In another embodiment of the method, the agent comprises nucleic acid molecule encoding DEAD-box protein of FIG. 4, SEQ ID NO:5 or a variant thereof.

In yet another embodiment of the method, the agent comprises nucleic acid molecule encoding 14-3-3 protein of FIG. 4, SEQ ID NO:5 or a variant thereof.

In a further embodiment of the method, the agent is administered with a pharmaceutically acceptable carrier.

The present invention provides a method of identifying a compound which can inhibit the replication of HCV,

wherein said compound inhibits hepatitis C virus replication by inhibiting the binding between HCV core protein and an agent capable of specifically binding to said HCV core protein, comprising: (a) incubating said compound, the HCV core protein and said agent under a suitable reaction conditions, (b) measuring the binding between the HCV core protein and said agent in the presence of said compound, and (c) comparing the binding in step (b) with the binding between the HCV core protein and said agent in the absence of said compound so as to identify a compound which can inhibit the replication of hepatitis C virus by inhibiting binding between HCV core protein and said agent.

In one embodiment of the method, the agent is known to bind to HCV core protein.

In another embodiment of the method, the binding of the agent to hepatitis C virus core protein prevents the hepatitis C virus from attaching to the cells of the subject so as to inhibit hepatitis C virus replication.

In another embodiment of the method, the binding of the agent to hepatitis C virus core protein prevents the hepatitis C virus from entering into the cells of the subject so as to inhibit hepatitis C virus replication.

In another embodiment of the method, the inhibition of HCV replication is in a subject.

In another embodiment of the method, the agent is a polypeptide, a pseudo enzyme, a peptidomimetic compound, a nucleic acid molecule, an antibody or variant thereof.

In another embodiment of the method, the agent comprises a cellular protein.

In another embodiment of the method, the cellular protein comprises a DEAD-box protein, or a 14-3-3 protein.

In another embodiment of the method, the DEAD box protein comprises a DEAD box RNA helicase.

In another embodiment of the method, the DEAD-box RNA helicase comprises a human DEAD-box protein DBX or a variant thereof.

In another embodiment of the method, the human DEAD-box protein DBX comprises the amino acid sequence of FIG. 2 SEQ ID NO:1.

In another embodiment of the method, the variant of the human DEAD-box protein DBX comprises the amino acid sequence of FIG. 2, SEQ ID NO:2.

In another embodiment of the method, the variant of the human DEAD-box protein DBX comprises the amino acid sequence of FIG. 3, SEQ ID NO:3.

In another embodiment of the method, the variant of the human DEAD-box protein DBX comprises 100–200 amino acid residues which mimics the amino acid sequence of FIG. 2, SEQ ID NO:2 or the amino acid sequence of FIG. 3, SEQ ID NO:3.

In another embodiment of the method, the 14-3-3 protein comprises the amino acid sequence of FIG. 4, SEQ ID NO:5 or a variant thereof.

In another embodiment of the method, the variant of said 14-3-3 protein comprises 50–200 amino acid residues which mimics the active site of said 14-3-3 protein of FIG. 4, SEQ ID NO:5.

In another embodiment of the method, the agent comprises nucleic acid molecule encoding DEAD-box protein of FIG. 2, SEQ ID NO:1 or a variant thereof.

In another embodiment of the method, the agent comprises nucleic acid molecule encoding 14-3-3 protein of FIG. 4, SEQ ID NO:5 or a variant thereof.

In another embodiment of the method, the agent comprises administered with a pharmaceutically acceptable carrier.

In another embodiment of the method, the inhibition of hepatitis C virus replication is *in vitro*.

In another embodiment of the method, the subject is a mammal.

In another embodiment of the method, the subject is a human.

In another embodiment of the method, the inhibition of hepatitis C virus replication occurs in the liver of the subject.

In another embodiment of the method, the inhibition of hepatitis C virus replication occurs in the liver of a human.

In another embodiment of the method, the binding between the HCV core protein and the agent is measured by yeast two-hybrid screening.

In yet another embodiment of the method, the compound is not previously known.

In a further embodiment of the method, the previously unknown compound is identified by the method.

The present invention also provides a composition comprising an effective amount of the compound identified by the method which is capable of inhibiting the binding between hepatitis C virus core protein and a cellular protein.

The present invention also provides a pharmaceutical composition comprising an effective amount of the compound identified by the method which is capable of treating or preventing hepatitis C virus infection.

The present invention also provides a method for determining whether a compound can treat or prevent hepatitis C virus infection in a subject, comprising (a) incubating said compound, the HCV core protein and an agent capable of specifically binding to said HCV core protein, (b) determining the binding between the HCV core protein and said agent in the presence of said compound, and (c) comparing the binding in step (b) with the binding between the HCV core protein and said agent in the absence of said compound so as to identify a compound which can treat or prevent hepatitis C virus infection in a subject, wherein said compound treats or prevents hepatitis C virus infection by specifically inhibiting the binding of HCV core protein and said agent so as to suppress hepatitis C virus replication.

In one embodiment of the method, the agent is known to bind to HCV core protein.

In another embodiment of the method, the binding of the agent to hepatitis C virus core protein prevents the hepatitis C virus from attaching to the cells of the subject so as to treat or prevent hepatitis C virus infection.

In another embodiment of the method, the binding of the agent to hepatitis C virus core protein prevents the hepatitis C virus from entering into the cells of the subject so as to treat or prevent hepatitis C virus infection.

In another embodiment of the method, the subject is a mammal.

In another embodiment of the method, the subject is a human.

In another embodiment of the method, the hepatitis C virus replication occurs in the liver of the subject.

In another embodiment of the method, the hepatitis C virus replication occurs in the liver of a human.

In another embodiment of the method, the compound can be administered orally or by injection.

In another embodiment of the method, the compound is not previously known.

In another embodiment of the method, the previously unknown compound is identified by said method.

In another embodiment of the method, the agent is a polypeptide, a pseudo enzyme, a peptidomimetic, a nucleic acid, an antibody or variant thereof.

In another embodiment of the method, the agent comprises a cellular protein.

In another embodiment of the method, the cellular protein comprises a DEAD-box protein, or a 14-3-3 protein.

In another embodiment of the method, the DEAD box protein comprises a DEAD box RNA helicase.

In another embodiment of the method, the DEAD-box RNA helicase comprises a human DEAD-box protein DBX or a variant thereof.

In another embodiment of the method, the human DEAD-box protein DBX comprises the amino acid sequence of FIG. 2 SEQ ID NO:1.

In another embodiment of the method, the variant of the human DEAD-box protein DBX comprises the amino acid sequence of FIG. 2, SEQ ID NO:2.

In another embodiment of the method, the variant of the human DEAD-box protein DBX comprises the amino acid sequence of FIG. 3, SEQ ID NO:3.

In another embodiment of the method, the variant of the human DEAD-box protein DBX comprises 100–200 amino acid residues which mimics the amino acid sequence of FIG. 2, SEQ ID NO:2 or the amino acid sequence of FIG. 3, SEQ ID NO:3.

In another embodiment of the method, the 14-3-3 protein comprises the amino acid sequence of FIG. 4, SEQ ID NO:5 or a variant thereof.

In another embodiment of the method, the variant of said 14-3-3 protein comprises 50–200 amino acid residues which mimics the active site of said 14-3-3 protein, FIG. 4, SEQ ID NO:5.

In another embodiment of the method, the agent comprises nucleic acid molecule encoding DEAD-box protein of FIG. 2, SEQ ID NO:1 or a variant thereof.

In yet another embodiment of the method, the agent comprises nucleic acid molecule encoding 14-3-3 protein of FIG. 4, SEQ ID NO:5 or a variant thereof.

In a further embodiment of the method, the agent comprises administered with a pharmaceutically acceptable carrier.

The present invention further provides a composition for inhibiting cell growth, comprises a HCV core protein or a variant thereof, wherein said HCV core protein or its variant inhibit cancer cell growth by inhibiting the cellular DEAD box proteins.

In one embodiment of the composition, the growth of cancer cells are inhibited.

As used herein, “subject” means any animal, including, for example, mice, rats, dogs, guinea pigs, ferrets, rabbits, and primates. In the preferred embodiment, the subject is a human.

“Cells” mean any cells, including, for example, lung cells, and kidney cells. In the preferred embodiment, the cells are liver cells. In a more preferred embodiment, the cells are human liver cells.

“Attachment” means the state of being firmly attached or bound through chemical or physical interactions or both. “Attachment of hepatitis C virus onto cells” means the hepatitis C virus being firmly attached or bound to the cell surface through the interaction between hepatitis C virus proteins, such as HCV core protein, and the HCV receptors located at the surface of the cells.

“Entry of HCV into cells” means the penetration of hepatitis C virus through the cell membrane into the cells from cell surface.

“Assembly” means association, binding, packing or aggregation. “HCV assembly” means the association of the single stranded HCV RNA with HCV coat proteins, the

formation of the single stranded HCV RNA—Coat Protein complex, or the packing of coat proteins onto the single stranded HCV RNA.

“HCV replication” means HCV reproduction within the cells.

“Hepatitis C virus infection” comprises the attachment of hepatitis C virus to cell surface, the entry of hepatitis C virus into cells, the replication of hepatitis C virus within the cells, and the death or transformation of the cells.

“Agent” means any biological molecule which specifically binds to HCV core protein. In one embodiment, the agent comprises a cellular protein.

“Nucleic acid molecule” means any natural or synthetic cDNA or mRNA.

As used herein, “suitable reaction conditions” means conditions under which an agent competitively bind to HCV core protein or a variant thereof.

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

#### Experimental Details

Yeast Two-Hybrid Screening: The Matchmaker Two-Hybrid System 2 was used to screen human liver Matchmaker cDNA library HL4002AB (Clontech) with the cytoplasmic domain (amino acids 1 to 123 that precedes the first predicted transmembrane segment) of HCV core protein as bait in the yeast two-hybrid assay (19). Library screening was performed using previously described methods (20, 29). To construct the bait plasmid, DNA encoding amino acids 1–123 of HCV core protein (numbering as in reference 8) was amplified by PCR with pHCV-1 (12), provided by M. Houghton (Chiron Corporation), as template. The HCV sequences in pHCV-1 derive from a library made from the plasma of an infectious chimpanzee (12). The amplified DNA was cloned into the GAL4 DNA binding domain fusion vector pAS2-1 (Clontech) to yield pAS2-1-HCV-core<sub>1-123</sub>. *Saccharomyces cerevisiae* strain Y190 was sequentially transformed with pAS2-1-HCV-core-123 and library recombinants in the GAL4 activation domain fusion vector pACT2 (Clontech). Positive pACT2-derived plasmids were rescued and used to co-transform yeast with pAS2-1-HCV-core1-123, pLAM5'-1 (Clontech) and pAS2-1 to confirm the specificity of the reactions. For analysis of PL10 and Ded1p binding, cDNAs encoding PL10 from amino acids 408 to 660 and Ded1p amino acids 368 to 604 (corresponding to the longest portion of DBX isolated in the two-hybrid screen) were amplified by PCR from template plasmids (23). The amplified cDNAs were cloned into pACT2 and used to co-transform yeast with pAS2-1-HCV-core<sub>1-123</sub>. DNA sequencing of isolated library plasmid inserts and the bait constructs was performed on a 373A Sequencer (Applied Biosystems) at the Columbia University Cancer Center DNA core facility. Sequence analysis was performed using the Wisconsin Package (Genetics Computer Group) and applications available via the Internet at the National Center for Biotechnology Information World Wide Web site (<http://www.ncbi.nlm.nih.gov/>).

In Vitro Binding Assays: A PCR product encoding the cytoplasmic domain of HCV core protein (amino acids 1–123) was cloned into pBFT4 for in vitro transcription-translation (26). DBX cDNA encoding amino acids 409 to 662 was excised from plasmid pACT2 by restriction endonuclease digestion and cloned into pGEX2T (Pharmacia Biotech) to yield pGEX2T-DBX409-662 that expressed a

glutathione-S-transferase (GST) fusion protein in *Escherichia coli*. Plasmid construction was confirmed by DNA sequencing. In vitro transcription-translation was performed with the TNT T7 Coupled Reticulocyte Lysate System (Promega) using L-[<sup>35</sup>S]-methionine (NEN). Binding assays were performed as described previously (26).

Cell Transfection and Confocal Immunofluorescence Microscopy: A PCR product encoding full-length HCV core protein (amino acids 1–191) obtained using pHCV-1 (12) as template was cloned in-frame into pBFT4 which contains an initiation codon and FLAG tag 5' to the cloning site. A DNA fragment was isolated by restriction endonuclease digestion at sites flanking the initiation and termination codons and cloned into pSVK3 (Pharmacia Biotech) to obtain pSVK3-FLAG-core for expression of HCV core protein with a FLAG tag at its amino-terminus. To obtain full-length DBX cDNA, PCR was performed using a Marathon-ready cDNA human liver library (Clontech) as template to amplify the first 1439 nucleotides of DBX cDNA which was ligated in-frame into pGEX2T-DBX409-662 to produce pGEX2T-DBX. The coding region of pGEX2T-DBX was isolated by restriction endonuclease digestion and cloned into pBluescript II SK<sup>-</sup> (Stratagene) to produce pBluescript-DBX. A cDNA containing the 3' 668 nucleotides of DBX, excluding the stop codon, was amplified by PCR and ligated into pBluescript II-DBX to replace the corresponding nucleotides. The entire DBX coding region was then excised by restriction endonuclease digestion and ligated into pcDNA3.1 (-)/Myc-His A (Invitrogen) to produce pcDNA3.1/His A-DBX-myc that encoded full-length DBX with a c-myc tag at its carboxyl-terminus. All plasmid constructs were confirmed by DNA sequencing. HeLa or COS-7 cells (ATCC) grown on glass slides were transfected with pSVK3-FLAG-core, pcDNA3.1/HIS A-DBX-myc or both using Tfx-20 (Promega) or DMRIE-C (Life Technologies). Cells were washed in phosphate-buffered saline 48 hours after transfection and fixed with methanol for 5 min at -20° C. followed by acetone at -20° C. for twenty seconds. Indirect immunofluorescence microscopy was performed as described (30). To detect express FLAG-tagged proteins in double-labeling experiments, FLAG-probe (Santa Cruz Biotechnology), a rabbit polyclonal antibody, was used. To reduce background, FLAG-probe was incubated with COS-7 cells fixed with methanol/acetone at a 1:100 dilution for twelve to sixteen hours prior to use. Anti-FLAG M2 monoclonal antibody (Eastman Kodak) was used in single-labeling experiments at a 1:200 dilution. Monoclonal anti-c-myc antibody 9E10 (Babco) was used at a 1:1000 dilution. Fluorescein isothiocyanate-conjugated goat anti-rabbit IgG and rhodamine-conjugated goat anti-mouse IgG secondary antibodies were obtained from Jackson Immuno Research Laboratories. Microscopy was performed using a Zeiss LSM 410 confocal laser scanning system attached to Zeiss Axiovert 100TV inverted microscope (Carl Zeiss). Images were processed using Photoshop software (Adobe) on a Macintosh G3 computer (Apple Computer).

Yeast Strains: Yeast strain YTC83 [MATa ded1::TRP1 ura3-52 lys2-801 ade2-101 trp1-D1 his3-D200 leu2-D1 pPL1004 (PL10/CEN/LEU2)], which contains a chromosomal ded1 deletion complemented by PL10 cDNA (23). To obtain a yeast strain with a chromosomal ded1 deletion complemented by DBX cDNA, full-length DBX cDNA was excised from pGEX2T-DBX by restriction endonuclease digestion and ligated into pRS315pG1. This plasmid was used to transform yeast strain YTC75 [MATa ded1::TRP1 ura3-52 lys2-801 ade2-101 trp1-D1 his3-D200 leu2-D1 pDED1008 (DED1/CEN/URA3)] (23), which was then

grown on leucine dropout plates. Transformants were replica-plated onto 5-fluoroorotic acid plates as described (31) to yield strain YNM1DX. To obtain a yeast strain with a chromosomal ded1 deletion complemented by DED1 cDNA driven by a glyceraldehyde-3-phosphate (GPD) promoter on a centromeric plasmid, the native promoter, 5' untranslated region and part of the 5' coding region were excised by restriction endonuclease digestion from pDED1009 (DED1/CEN/LEU2). The GPD promoter, isolated from pRS315pG1 by restriction endonuclease digestion, and 477 5' coding nucleotides of DED1, amplified by PCR, were then sequentially ligated into this pDED1009-derived plasmid to yield pDED<sub>GPD</sub>. Yeast strain YTC75 was then transformed with pDED<sub>GPD</sub> and 5-fluoroorotic acid counter-selection performed to obtain strain YNM1DD [MATa ded1::TRP1 ura3-52 lys2-801 ade2-101 trp1-D1 his3-D200 leu2-D1 pDED<sub>GPD</sub> (DED1/CEN/LEU2)]. All constructs were confirmed by DNA sequencing.

Effects of HCV Core Protein on Growth of Yeast Strains:

The coding region for full-length HCV core protein (amino acid 1-191) was excised from pBFT4 by restriction endonuclease digestion and ligated into p423GPD (ATCC) to produce p423GPD-core. The coding region for the cytoplasmic domain of HCV core protein (amino acid 1-123) was also ligated into p423GPD to yield p423GPD-core<sub>1-123</sub>. Constructs were confirmed by DNA sequencing. Yeast strains YTC83, YNM1DX and YNM1DD were transformed with p423GPD, p423GPD-core and p423GPD-core<sub>1-123</sub> using the lithium acetate-mediated method (24) and grown on histidine-leucine dropout plates for seven days. Plates were photographed to record colony growth.

Effect of HCV Core Protein on In Vitro Translation: cDNA encoding HCV core protein from amino acids 1 to 123 was ligated into pGEX4T-3 (Pharmacia) to produce a GST fusion protein (GST-core<sub>1-123</sub>) in *Escherichia coli*. Plasmid construction was confirmed by DNA sequencing. pGEM-luc (Promega) was linearized with XhoI and used as a template for luciferase RNA transcription with the RiboMAX RNA Production System-SP6 (Promega). When capped RNA was synthesized, 3 mM of <sup>7</sup>mGpppG (New England Biolabs) was included in the reaction mixture. The DNA template was removed by digestion with DNase following the transcription reaction and synthesized mRNA was purified using the RNeasy Mini Kit (Qiagen). For in vitro translation, 16.5 μl of Flexi Rabbit Reticulocyte Lysate (Promega) was used and incubated for one hour at 4° C. with 8.25 μl of glutathione-Sepharose 4B (Pharmacia Biotech) loaded with either 300 ng of GST-core<sub>1-123</sub> or GST followed by centrifugation for 5 minutes at 2000×g. Translation reactions were then performed according to the manufacturer's instructions and luciferase activity measured by luminescence emission using the Luciferase Assay System (Promega).

HCV Core Protein Binding to DBX: Screening of 8×10<sup>6</sup> recombinants of a human liver cell cDNA library with the cytoplasmic domain of HCV core protein as bait in the yeast two-hybrid assay led to the isolation of 5 positive clones, 3 of which encoded portions of DBX, the longest from amino acid 409 to amino acid 662. The two other positive clones encoded portions of epsilon 14-3-3 (See FIG. 4), a member of the 14-3-3 family of proteins that have numerous proposed functions, including activities in signal transduction. DBX is the human orthologue of the mouse DEAD-box protein PL10 (21-22, 32). PL10 is the functional orthologue of *Saccharomyces cerevisiae* Ded1p, an ATP-dependent RNA helicase for capped mRNA (23). DBX is 95% identical in primary structure to PL10 and 54% identical to Ded1p

(FIG. 6A). In the yeast two-hybrid assay, HCV core protein interacts with DBX and PL10 but not with Ded1p (FIG. 6B).

We confirmed the interaction between HCV core protein and DBX in an in vitro binding assay. The cytoplasmic domain of HCV core protein was synthesized by in vitro translation and incubated with GST or a GST-fusion protein containing DBX from amino acid 409 to amino acid 662. Proteins were precipitated with glutathione-Sepharose and HCV core protein binding was analyzed by autoradiography. HCV core protein did not bind to GST but did bind to GST-DBX fusion protein in buffers containing NaCl concentrations as high as 1 Molar (FIG. 5A). Binding also occurred in buffers containing 1% of the non-ionic detergent Nonidet P-40 (FIG. 5B).

Co-localization of HCV Core Protein and DBX in Cells: An interaction between HCV core protein and DBX in mammalian cells was further supported by their intracellular co-localization. Indirect confocal immunofluorescence microscopy of transfected HeLa cells showed that full-length HCV core protein, which contains the cytoplasmic domain and a single transmembrane segment, was localized to the endoplasmic reticulum in discrete foci (FIG. 7A). A similar localization in the endoplasmic reticulum has been reported by others (12). Focal aggregates of HCV core protein likely arise because this polypeptide multimerizes (13). In cells not expressing HCV core protein, DBX had a more diffuse cytoplasmic distribution (FIG. 7A). In cells expressing HCV core protein, however, DBX was found in most instances in discrete foci that co-localized with HCV core protein (FIG. 7B). The antibodies used to detect the respective epitope tags of each protein did not cross-react significantly (FIG. 7B). HCV core protein therefore forms aggregates at the endoplasmic reticulum membrane with which DBX apparently associates.

DBX Rescues Ded1-deletion Yeast Mutants and Rescue is Prevented by HCV Core: DBX likely functions as an ATP-dependent RNA helicase for cellular mRNA, which can be inferred from its sequence similarity to mouse PL10 and yeast Ded1p (22-23). To examine the effect of HCV core protein on DBX function, we took advantage of yeast genetics and the fact that *Saccharomyces cerevisiae* has only one essential DBX-like protein, Ded1p (23). When driven by a yeast GPD promoter and carried on a centromere plasmid, mouse PL10 cDNA, as previously described (23), and DBX cDNA rescued the lethality of cells with a chromosomal ded1 deletion. This indicates that DBX can likely function as a RNA helicase as it can replace the function of the yeast DEAD-box RNA helicase Ded1p. Expression of full-length HCV core protein severely inhibited the growth of DBX- and PL10- complemented ded1-deletion yeast but not ded1-deletion yeast complemented with DED1 cDNA driven by the same promoter on a centromeric plasmid (FIG. 8). This is consistent with the observation that DBX and PL10, but not Ded1p, bind to HCV core protein. The cytoplasmic domain of HCV core protein that binds to DBX, without a transmembrane segment, did not significantly inhibit the growth of DBX- and PL10- complemented ded1-deletion yeast (data not shown), suggesting that inhibition of function may result from trapping of these proteins in aggregates at the endoplasmic reticulum membrane (see FIG. 7).

Inhibition of In Vitro Translation of Capped mRNA by HCV Core Protein: We examined the effects of HCV core protein on the translation of capped and uncapped luciferase RNA in an in vitro reticulocyte lysate assay. If HCV inhibits DBX's function as a RNA helicase, it should theoretically decrease the translation of capped RNA while but not

significantly affect the translation of uncapped RNA. In the in vitro translation assay, the cytoplasmic portion of HCV core protein significantly inhibited the in vitro translation of luciferase from capped but not uncapped RNA (FIG. 9). Capped RNA translation was approximately four-fold higher than uncapped RNA translation in this assay (data not shown). This finding suggests that HCV core protein may inhibit the translation of capped mRNA in cells, presumably by inhibiting DBX function.

HCV core protein binds to the human DEAD-box protein DBX: DBX rescues the lethal phenotype of ded1-deletion demonstrating that it can function as a RNA helicase for capped mRNA, replacing the essential yeast DEAD-box RNA helicase Ded1p. Our findings that HCV core protein prevents DBX from rescuing ded1-deletion yeast and that it inhibits the translation of capped RNA in vitro strongly suggest that it may inhibit cellular mRNA translation in vivo. These results, however, cannot establish if translation inhibition occurs as a result of HCV core protein inhibiting DBX RNA helicase activity per se or by an interaction that results in trapping DBX at a location near the membrane of the endoplasmic reticulum where it cannot function properly. Inhibition of host cell mRNA translation could theoretically provide viral RNA molecules with enhanced access to ribosomes and the rest of the cell's protein synthesis machinery, a phenomenon shared by several different viruses (33). A recent report has shown that high levels of expression of HCV structural and non-structural proteins is toxic to mammalian cells (34), however, it is not clear if this toxicity results from inhibition of host cell translation. Because the development of a robust cell culture system to study HCV has remained elusive, it would be extremely difficult to directly investigate the effects of HCV infection on host cell mRNA translation. Despite these methodological constraints limiting the ability to directly test the hypothesis, our discovery that HCV core binds to DBX and inhibits capped RNA translation in experimental assays suggests that it can similarly inhibit mRNA translation in infected human cells.

DEAD-box RNA helicases unwind capped mRNA (23) and inhibition of their function should decrease translation of cellular mRNA. Inhibition of DBX function by HCV core protein may only partially inhibit host mRNA translation in mammalian cells because they contain other putative RNA helicases (35). In contrast, the translation of HCV RNA, which is not capped, utilizes internal ribosome entry sites (10, 11) and can be unwound by its own RNA helicase that is part of the HCV NS3 protein (36, 37), may proceed without DBX. This hypothetical mechanism is reminiscent of that used by poliovirus which inhibits translation factor eIF-4F (38, 39) and also has RNA with internal ribosome entry sites (40). In cells, eIF-4F exists as a complex with eIF-4B, which has RNA binding activity, and eIF-4A, which is also a DEAD-box RNA helicase (41). HCV and poliovirus infection may both therefore cause a decrease in the unwinding of capped mRNA in host cells.

In addition to inhibiting capped mRNA translation in infected host cells, the interaction between HCV core protein and DBX may play other possible roles, including the recruitment of DBX to participate in HCV replication itself. Recruitment of host cell proteins into virions to enhance viral replication has been demonstrated in other systems. For example, the principal structural protein of the human immunodeficiency virus HIV-1 binds to cyclophilins and recruits cyclophilin A into viral particles, which appears to be necessary for efficient viral replication (42, 43). In a

similar fashion, recruitment of DBX into HCV particles by binding to core protein may enhance viral replication. This could theoretically occur by DBX altering viral genomic RNA structure in viral particles of in newly infected cells. Testing of this hypothesis is limited at the present time because of the lack of an efficient cell culture system for HCV.

HCV core protein has also been shown to bind to lymphotoxin- $\beta$  receptor and other tumor necrosis factor receptor family members (15, 27) as well as ribonucleoprotein K (28). In our yeast two-hybrid screen, we did not isolate clones for these proteins, possibly because of subtle differences in our bait construct and the different cDNA library we used. The demonstration that other proteins interact with HCV core protein suggests that its expression in cells may have myriad consequences. Other groups (18, 44) have also reported that HCV core protein represses transcription from the p53 promoter and other eukaryotic promoters. The overall effect of HCV core protein on cell physiology under natural conditions of infection is, however, difficult to assess at the present time because of lack of a cell culture system for HCV.

Finally, it should be noted that the best current treatment regimens for chronic hepatitis C are effective in only a minority of patients (45). If interactions between HCV and host cell proteins alter cell survival or enhance viral replication, they could be rational targets for antiviral drug design. Regardless of the physiological significance, the tight binding of any polypeptide to a structural or non-structural protein of HCV may potentially interfere with viral replication. The identification of polypeptides such as DBX that bind to HCV proteins therefore has implications for the design of compounds which may be therapeutically useful in the treatment of patients with chronic hepatitis C.

Compounds that specifically target HCV can be developed to treat HCV infection. Possible targets are the HCV proteases, RNA helicase and RNA polymerase. As the three-dimensional structures of the NS3 protease and helicase are known, rational drug design in combination with combinatorial chemistry may lead to the development of inhibitors. Other possible targets are the 5' untranslated region of the viral RNA that uses a different mechanism of ribosome entry than most host cell RNAs. The major viral structural protein (core protein, envelope proteins E1 and E2) can also be targeted for treating HCV infection. Inhibitors of core protein and envelope protein binding to critical cellular proteins could also be useful therapeutic agents.

## REFERENCES

1. Mamiya, N., and Worman, H. J. (1997) "Epidemiology, prevention, clinical features and therapy of hepatitis B, C and G." *Curr. Opin. Infect. Dis.*, 10:3990-397;
2. Alter, M. J. (1997) "Epidemiology of hepatitis C." *Hepatology*, 26:62S-65S;
3. Choo, Q.-L., et al. (1989) "Isolation of a cDNA clone derived from blood-borne nonA, nonB viral hepatitis genome" *Science*, 244:359-362;
4. Kuo, G., et al. (1989) "An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis" *Science*, 244:359-363;
5. National Institutes of Health Consensus Development Conference Panel Statement (1997) "Management of Hepatitis C" *Hepatology*, 26:2S-10S;
6. Kato, N., et al. (1990) "Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis" *Proc. Natl. Acad. Sci. U.S.A.*, 87:9524-9528;
7. Choo, Q.-L., et al. (1991) "Genetic organization and diversity of the hepatitis C virus" *Proc. Natl. Acad. Sci. U.S.A.*, 88:2451-2455;
8. Okamoto, H., et al. (1991) "Nucleotide sequence of the genomic RNA hepatitis C virus isolated from a human carrier: comparison with reported isolates from conserved and divergent regions" *J. Gen. Virol.*, 72:6697-6704;
9. Takamizawa, A., et al. (1991) "Structure and organization of the hepatitis C genome isolated from human carriers" *J. Virol.*, 65:1105-1113;
10. Reynolds, J. E., et al. (1995) "Unique features of internal initiation of hepatitis C virus RNA translation" *EMBO J.*, 14:6010-6020;
11. Fukushi, S., et al. (1997) "The sequence element of the internal ribosome entry site and a 25-kilodalton cellular protein contribute to efficient internal initiation of translation of hepatitis C virus RNA" *J. Virol.*, 71:1662-1666;
12. Selby, M. J., et al. (1993) "Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome" *J. Gen. Virol.*, 74:1103-1113;
13. Matsumoto, M., et al. (1996) "Homotypic interactions and multimerization of the hepatitis C virus core protein" *Virology*, 218:43-51;
14. Ray, R. B., et al. (1996) "Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype" *J. Virol.*, 70:4438-4443;
15. Matsumoto, M., et al. (1997) "Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin- $\beta$  receptor" *J. Virol.*, 71:1301-1309;
16. Lanford, R. E., et al. (1993) "Analysis of hepatitis C virus capsid, E1, and E2/NS1 proteins expressed in insect cells" *Virology*, 197:225-235;
17. Suzuki, R., et al. "Nuclear localization of the truncated hepatitis C virus core protein with its hydrophobic C terminus deleted" *J. Gen. Virol.*, 76:53-61;
18. Ray, R. B., et al. (1997) "Transcriptional repression of p53 promoter by hepatitis C virus core protein" *J. Biol. Chem.*, 272:10983-10986;
19. Fields, S., and Song, O. (1989) "A novel genetic system to detect protein-protein interactions" *Nature*, 340:245-246;
20. Chien, C., et al. (1991) "The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest" *Proc. Natl. Acad. Sci. U.S.A.*, 88:9578-9582;
21. Lahn, B. T., and Page, D. C. (1997) "Functional coherence of the human Y chromosome" *Science*, 278:675-680;
22. Leroy, P., et al. (1989) "The protein encoded by a murine male germ cell-specific transcript is a putative ATP-dependent RNA helicase" *Cell*, 57:549-559;
23. Chuang, R.-Y., et al. (1997) "Requirement of the DEAD-box protein Ded1p for messenger RNA translation" *Science*, 275:1468-1471;
24. Saiki, R. K., et al. (1988) "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase" *Science*, 239:487-491;
25. Smith, D. B. and Johnson, K. S. (1988) "Single-step purification of polypeptides expressed in *Escherichia coli* as fusions with glutathione-S-transferase" *Gene.*, 67:31-40;

26. Ye, Q., and Worman, H. J. (1996) "Interaction between an integral protein of the nuclear envelope inner membrane and human chromodomain proteins homologous to *Drosophila* HP1" *J. Biol. Chem.*, 271:14653-14656;
27. Zhu, N., et al. (1998) *J. Virol.* 72, 3691-3697;
28. Hsieh, T.-Y., et al. (1998) *J. Biol. Chem.*, 271, 17651-17659;
29. Durfee, T., Becherer, K., Chen, P. L., Yeh, S. H., Yang, Y., Kilburn, A. E., Lee, W. H., and Elledge, S. J. (1993) *Genes Dev.* 7, 555-569;
30. Soullam, B., and Worman, H. J. (1995) *J. Cell Biol.* 130, 15-27;
31. Boeke, J. D., Trueheart, J., Natsoulis, G., and Fink, G. R. (1987) *Methods Enzymol.* 154, 164-175;
32. Chung, J., Lee, S., and Song, K. (1995) *Korean J. Biochem.* 27, 193-197;
33. Knipe, D. M. (1996) in *Field's Virology*, eds. Fields, B. N., Knipe, D. M., and Howley, P. M. (Lippincott-Raven Publishers, Philadelphia), 3rd Ed., pp. 273-299;

34. Moradpour, D., Kary, P., Rice, C. M., and Slum, H. E. (1998) *Hepatology.* 28, 192-201;
35. Gee, S. L., and Conboy, J. G. (1994) *Gene*, 140: 171-177;
36. Yao, N., et al. (1997) *Nat. Struct. Biol.*, 4: 463-467;
37. Kim, J. L., et al. (1998) *Structure*, 6: 89-100;
38. Rose, J. K., et al. (1978) *Proc. Natl. Acad. Sci. U.S.A.*, 75: 2732-2736;
39. Etchison, D., et al. (1982) *J. Biol. Chem.*, 14806-14810;
40. Pelletier, J., and Sonenberg, N. (1988) *Nature*, 334: 320-325;
41. Rozen, F., et al. (1990) *Mol. Cell Biol.*, 10: 1134-1144;
42. Luban, J., et al. (1993) *Cell*, 18: 1067-1078;
43. Franke, E. K., et al. (1994) *Nature*, 372: 359-362;
44. Kim, D. W., et al. (1994) *Jpn. J. Med. Sci. Biol.*, 47: 211-220; and
45. Liang, T. J. (1998) *N. Eng. J. Med.*, 339: 1549-1550.

## SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 6

<210> SEQ ID NO 1

<211> LENGTH: 666

<212> TYPE: PRT

<213> ORGANISM: Human

<400> SEQUENCE: 1

```

Met Ser His Val Ala Val Glu Asn Ala Leu Gly Leu Asp Gln Gln Phe
 1             5             10             15
Ala Gly Leu Asp Leu Asn Ser Ser Asp Asn Gln Ser Gly Gly Ser Thr
 20             25             30
Ala Ser Lys Gly Arg Tyr Ile Pro Pro His Leu Arg Asn Arg Glu Ala
 35             40             45
Thr Arg Gly Phe Tyr Asp Lys Asp Ser Ser Gly Trp Ser Ser Ser Lys
 50             55             60
Asp Lys Asp Ala Tyr Ser Ser Phe Gly Ser Arg Ser Asp Ser Arg Gly
 65             70             75             80
Lys Ser Ser Phe Phe Ser Asp Arg Gly Ser Gly Ser Arg Gly Arg Phe
 85             90             95
Phe Asp Asp Arg Gly Arg Ser Asp Tyr Asp Gly Ile Gly Ser Arg Gly
100             105             110
Asp Arg Ser Gly Arg Gly Lys Phe Glu Arg Gly Gly Asn Ser Arg Trp
115             120             125
Cys Asp Lys Ser Asp Glu Asp Asp Trp Ser Lys Pro Leu Pro Pro Ser
130             135             140
Glu Arg Leu Glu Gln Glu Leu Phe Ser Gly Gly Asn Thr Gly Ile Asn
145             150             155             160
Phe Glu Lys Tyr Asp Asp Ile Pro Val Glu Ala Thr Gly Asn Asn Cys
165             170             175
Pro Pro His Ile Glu Ser Phe Ser Asp Val Val Val Glu Met Gly Glu
180             185             190
Ile Ile Met Gly Asn Ile Glu Leu Thr Arg Tyr Thr Arg Pro Thr Pro
195             200             205
Val Gln Lys His Ala Ile Pro Ile Ile Lys Glu Lys Arg Asp Leu Met
210             215             220

```



-continued

---

645	650	655
Asn Ser Gln Gly Val Asp Trp Trp Gly Asn		
660	665	

<210> SEQ ID NO 2  
 <211> LENGTH: 254  
 <212> TYPE: PRT  
 <213> ORGANISM: Human

<400> SEQUENCE: 2

Gly Ser Thr Ser Glu Asn Ile Thr Gln Lys Val Val Trp Val Glu Glu		
1	5	10
Ser Asp Lys Arg Ser Phe Leu Leu Asp Leu Leu Asn Ala Thr Gly Lys		
20	25	30
Asp Ser Leu Thr Leu Val Phe Val Glu Thr Lys Lys Gly Ala Asp Ser		
35	40	45
Leu Glu Asp Phe Leu Tyr His Glu Gly Tyr Ala Cys Thr Ser Ile His		
50	55	60
Gly Asp Arg Ser Gln Arg Asp Arg Glu Glu Ala Leu His Gln Phe Arg		
65	70	75
Ser Gly Lys Ser Pro Ile Leu Val Ala Thr Ala Val Ala Ala Arg Gly		
85	90	95
Leu Asp Ile Ser Asn Val Lys His Val Ile Asn Phe Asp Leu Pro Ser		
100	105	110
Asp Ile Glu Tyr Val His Arg Ile Gly Arg Thr Gly Arg Val Gly		
115	120	125
Asn Leu Gly Leu Ala Thr Ser Phe Phe Asn Glu Arg Asn Ile Asn Ile		
130	135	140
Thr Lys Asp Leu Leu Asp Leu Leu Val Glu Ala Lys Gln Glu Val Pro		
145	150	155
Ser Trp Leu Glu Asn Met Ala Tyr Glu His His Tyr Lys Gly Ser Ser		
165	170	175
Arg Gly Arg Ser Lys Ser Ser Arg Phe Ser Gly Gly Phe Gly Ala Arg		
180	185	190
Asp Tyr Arg Gln Ser Ser Gly Ala Ser Ser Ser Ser Phe Ser Ser Ser		
195	200	205
Arg Ala Ser Ser Ser Arg Ser Gly Gly Gly Gly His Gly Ser Ser Arg		
210	215	220
Gly Phe Gly Gly Gly Gly Tyr Gly Gly Phe Tyr Asn Ser Asp Gly Tyr		
225	230	235
Gly Gly Asn Tyr Asn Ser Gln Gly Val Asp Trp Trp Gly Asn		
245	250	

<210> SEQ ID NO 3  
 <211> LENGTH: 136  
 <212> TYPE: PRT  
 <213> ORGANISM: Human

<400> SEQUENCE: 3

Val Gly Ser Thr Ser Glu Asn Ile Thr Gln Lys Val Val Trp Val Glu		
1	5	10
Glu Ser Asp Lys Arg Ser Phe Leu Leu Asp Leu Leu Asn Ala Thr Gly		
20	25	30
Lys Asp Ser Leu Thr Leu Val Phe Val Glu Thr Lys Lys Gly Ala Asp		
35	40	45
Ser Leu Glu Asp Phe Leu Tyr His Glu Gly Tyr Ala Cys Thr Ser Ile		

-continued

50	55	60	
His Gly Asp Arg Ser	Gln Arg Asp Arg	Glu Glu Ala Leu His Gln Phe	
65	70	75	80
Arg Ser Gly Lys Ser	Pro Ile Leu Val	Ala Thr Ala Val Val Ala Ala	
	85	90	95
Arg Gly Leu Asp Ile	Ser Asn Val Lys	His Val Ile Asn Phe Asp Leu	
	100	105	110
Pro Ser Asp Ile Glu	Glu Tyr Val His	Arg Ile Gly Arg Thr Gly Arg	
	115	120	125
Val Gly Asn Leu Gly	Leu Ala Thr		
	130	135	
<210> SEQ ID NO 4			
<211> LENGTH: 792			
<212> TYPE: DNA			
<213> ORGANISM: Human			
<220> FEATURE:			
<221> NAME/KEY: CDS			
<222> LOCATION: (1)..(765)			
<400> SEQUENCE: 4			
atg gat gat cga gag gat ctg gtg tac cag gcg aag ctg gcc gag cag			48
Met Asp Asp Arg Glu Asp Leu Val Tyr	Gln Ala Lys Leu Ala Glu Gln		
1	5	10	15
gct gag cga tac gac gaa atg gtg gag tca atg aag aaa gta gca ggg			96
Ala Glu Arg Tyr Asp Glu Met Val Glu Ser Met Lys Lys Val Ala Gly			
	20	25	30
atg gat gtg gag ctg aca gtt gaa gaa aga aac ctc cta tct gtt gca			144
Met Asp Val Glu Leu Thr Val Glu Glu Arg Asn Leu Leu Ser Val Ala			
	35	40	45
tat aag aat gtg att gga gct aga aga gcc tcc tgg aga ata atc agc			192
Tyr Lys Asn Val Ile Gly Ala Arg Arg Ala Ser Trp Arg Ile Ile Ser			
	50	55	60
agc att gaa cag aaa gaa gaa aac aag gga gga gaa gac aag cta aaa			240
Ser Ile Glu Gln Lys Glu Glu Asn Lys Gly Gly Glu Asp Lys Leu Lys			
	65	70	75
atg att cgg gaa tat cgg caa atg gtt gag act gag cta aag tta atc			288
Met Ile Arg Glu Tyr Arg Gln Met Val Glu Thr Glu Leu Lys Leu Ile			
	85	90	95
tgt tgt gac att ctg gat gta ctg gac aaa cac ctc att cca gca gct			336
Cys Cys Asp Ile Leu Asp Val Leu Asp Lys His Leu Ile Pro Ala Ala			
	100	105	110
aac act ggc gag tcc aag gtt ttc tat tat aaa atg aaa ggg gac tac			384
Asn Thr Gly Glu Ser Lys Val Phe Tyr Tyr Lys Met Lys Gly Asp Tyr			
	115	120	125
cac agg tat ctg gca gaa ttt gcc aca gga aac gac agg aag gag gct			432
His Arg Tyr Leu Ala Glu Phe Ala Thr Gly Asn Asp Arg Lys Glu Ala			
	130	135	140
gcg gag aac agc cta gtg gct tat aaa gct gct agt gat att gca atg			480
Ala Glu Asn Ser Leu Val Ala Tyr Lys Ala Ala Ser Asp Ile Ala Met			
	145	150	155
aca gaa ctt cca cca acg cat cct att cgc tta ggt ctt gct ctc aat			528
Thr Glu Leu Pro Pro Thr His Pro Ile Arg Leu Gly Leu Ala Leu Asn			
	165	170	175
ttt tcc gta ttc tac tac gaa att ctt aat tcc cct gac cgt gcc tgc			576
Phe Ser Val Phe Tyr Tyr Glu Ile Leu Asn Ser Pro Asp Arg Ala Cys			
	180	185	190
agg ttg gca aaa gca gct ttt gat gat gca att gca gaa ctg gat acg			624
Arg Leu Ala Lys Ala Ala Phe Asp Asp Ala Ile Ala Glu Leu Asp Thr			
	195	200	205

-continued

```

ctg agt gaa gaa agc tat aag gac tct aca ctt atc atg cag ttg tta      672
Leu Ser Glu Glu Ser Tyr Lys Asp Ser Thr Leu Ile Met Gln Leu Leu
    210                               215                               220

cgt gat aat ctg aca cta tgg act tca gac atg cag ggt gac ggt gaa      720
Arg Asp Asn Leu Thr Leu Trp Thr Ser Asp Met Gln Gly Asp Gly Glu
225                               230                               235                               240

gag cag aat aaa gaa gcg ctg cag gac gtg gaa gac gaa aat cag      765
Glu Gln Asn Lys Glu Ala Leu Gln Asp Val Glu Asp Glu Asn Gln
    245                               250                               255

tgagacataa gccacaaga gaaacca      792
    
```

```

<210> SEQ ID NO 5
<211> LENGTH: 255
<212> TYPE: PRT
<213> ORGANISM: Human
    
```

<400> SEQUENCE: 5

```

Met Asp Asp Arg Glu Asp Leu Val Tyr Gln Ala Lys Leu Ala Glu Gln
  1                               5                               10                               15

Ala Glu Arg Tyr Asp Glu Met Val Glu Ser Met Lys Lys Val Ala Gly
    20                               25                               30

Met Asp Val Glu Leu Thr Val Glu Glu Arg Asn Leu Leu Ser Val Ala
    35                               40                               45

Tyr Lys Asn Val Ile Gly Ala Arg Arg Ala Ser Trp Arg Ile Ile Ser
    50                               55                               60

Ser Ile Glu Gln Lys Glu Glu Asn Lys Gly Gly Glu Asp Lys Leu Lys
    65                               70                               75                               80

Met Ile Arg Glu Tyr Arg Gln Met Val Glu Thr Glu Leu Lys Leu Ile
    85                               90                               95

Cys Cys Asp Ile Leu Asp Val Leu Asp Lys His Leu Ile Pro Ala Ala
    100                              105                              110

Asn Thr Gly Glu Ser Lys Val Phe Tyr Tyr Lys Met Lys Gly Asp Tyr
    115                              120                              125

His Arg Tyr Leu Ala Glu Phe Ala Thr Gly Asn Asp Arg Lys Glu Ala
    130                              135                              140

Ala Glu Asn Ser Leu Val Ala Tyr Lys Ala Ala Ser Asp Ile Ala Met
    145                              150                              155                              160

Thr Glu Leu Pro Pro Thr His Pro Ile Arg Leu Gly Leu Ala Leu Asn
    165                              170                              175

Phe Ser Val Phe Tyr Tyr Glu Ile Leu Asn Ser Pro Asp Arg Ala Cys
    180                              185                              190

Arg Leu Ala Lys Ala Ala Phe Asp Asp Ala Ile Ala Glu Leu Asp Thr
    195                              200                              205

Leu Ser Glu Glu Ser Tyr Lys Asp Ser Thr Leu Ile Met Gln Leu Leu
    210                              215                              220

Arg Asp Asn Leu Thr Leu Trp Thr Ser Asp Met Gln Gly Asp Gly Glu
    225                              230                              235                              240

Glu Gln Asn Lys Glu Ala Leu Gln Asp Val Glu Asp Glu Asn Gln
    245                              250                              255
    
```

```

<210> SEQ ID NO 6
<211> LENGTH: 1928
<212> TYPE: PRT
<213> ORGANISM: Human
    
```

<400> SEQUENCE: 6

-continued

Met	Ser	His	Val	Ala	Val	Glu	Asn	Ala	Leu	Gly	Leu	Asp	Gln	Gln	Phe
1				5					10					15	
Ala	Gly	Leu	Asp	Leu	Asn	Ser	Ser	Asp	Asn	Gln	Ser	Gly	Gly	Ser	Thr
			20					25					30		
Ala	Ser	Lys	Gly	Arg	Tyr	Ile	Pro	Pro	His	Leu	Arg	Met	Ser	His	Val
		35					40					45			
Ala	Glu	Glu	Asp	Glu	Leu	Gly	Leu	Asp	Gln	Gln	Leu	Ala	Gly	Leu	Asp
		50				55					60				
Leu	Thr	Ser	Arg	Asp	Ser	Gln	Ser	Gly	Gly	Ser	Thr	Ala	Ser	Lys	Gly
		65				70				75					80
Arg	Tyr	Ile	Pro	Pro	His	Leu	Arg	Met	Ala	Glu	Leu	Ser	Glu	Gln	Val
				85					90						95
Gln	Asn	Leu	Ser	Ile	Asn	Asp	Asn	Asn	Glu	Asn	Gly	Tyr	Val	Pro	Pro
			100					105						110	
His	Leu	Arg	Gly	Lys	Pro	Arg	Ser	Ala	Arg	Asn	Asn	Ser	Ser	Asn	Tyr
		115					120					125			
Asn	Asn	Asn	Asn	Asn	Arg	Glu	Ala	Thr	Arg	Gly	Phe	Tyr	Asp	Lys	Asp
		130				135					140				
Ser	Ser	Gly	Trp	Ser	Ser	Ser	Lys	Asp	Lys	Asp	Ala	Tyr	Ser	Ser	Phe
		145				150				155					160
Gly	Ser	Arg	Ser	Asp	Ser	Arg	Gly	Lys	Ser	Ser	Phe	Phe	Ser	Asp	Arg
				165					170					175	
Gly	Ser	Gly	Ser	Arg	Gly	Arg	Phe	Asp	Asp	Arg	Gly	Arg	Ser	Asn	Arg
			180					185					190		
Glu	Ala	Ala	Lys	Ala	Phe	Tyr	Asp	Lys	Asp	Gly	Ser	Arg	Trp	Ser	Lys
		195					200					205			
Asp	Lys	Asp	Ala	Tyr	Ser	Ser	Phe	Gly	Ser	Arg	Ser	Asp	Thr	Arg	Ala
		210				215					220				
Lys	Ser	Ser	Phe	Phe	Ser	Asp	Arg	Gly	Gly	Ser	Gly	Ser	Arg	Gly	Arg
		225				230				235					240
Phe	Asp	Glu	Arg	Gly	Arg	Ser	Asp	Gly	Gly	Tyr	Asn	Gly	Gly	Arg	Gly
				245					250					255	
Gly	Gly	Ser	Phe	Phe	Ser	Asn	Asn	Arg	Arg	Gly	Gly	Tyr	Gly	Asn	Gly
			260					265					270		
Gly	Phe	Phe	Gly	Gly	Asn	Asn	Gly	Gly	Ser	Arg	Ser	Asn	Gly	Arg	Ser
		275					280					285			
Gly	Gly	Arg	Trp	Ile	Asp	Gly	Lys	His	Val	Pro	Ala	Pro	Arg	Asn	Glu
		290				295					300				
Lys	Ala	Asp	Tyr	Asp	Gly	Ile	Gly	Ser	Arg	Gly	Asp	Arg	Ser	Gly	Phe
		305				310				315					320
Gly	Lys	Phe	Glu	Arg	Gly	Gly	Asn	Ser	Arg	Trp	Cys	Asp	Lys	Ser	Asp
				325					330					335	
Glu	Asp	Asp	Trp	Ser	Lys	Pro	Leu	Pro	Pro	Ser	Glu	Arg	Leu	Glu	Gln
			340					345					350		
Glu	Leu	Phe	Ser	Gly	Gly	Asn	Thr	Gly	Ile	Asn	Phe	Tyr	Glu	Ser	Val
		355					360					365			
Gly	Ser	Arg	Gly	Gly	Arg	Ser	Gly	Phe	Gly	Lys	Phe	Glu	Arg	Gly	Gly
		370				375					380				
Asn	Ser	Arg	Trp	Cys	Asp	Lys	Ala	Asp	Glu	Asp	Asp	Trp	Ser	Lys	Pro
					390					395					400
Leu	Pro	Pro	Ser	Glu	Arg	Leu	Glu	Gln	Glu	Leu	Phe	Ser	Gly	Gly	Asn
				405					410					415	
Thr	Gly	Ile	Asn	Phe	Glu	Glu	Ile	Ala	Ile	Phe	Gly	Val	Pro	Glu	Asp

-continued

420					425					430					
Pro	Asn	Phe	Gln	Ser	Ser	Gly	Ile	Asn	Phe	Asp	Asn	Tyr	Asp	Asp	Ile
	435						440					445			
Pro	Val	Asp	Ala	Ser	Gly	Lys	Asp	Val	Pro	Glu	Pro	Ile	Thr	Glu	Phe
	450					455					460				
Thr	Ser	Pro	Pro	Leu	Asp	Gly	Leu	Leu	Leu	Glu	Asn	Ile	Lys	Leu	Ala
	465				470					475					480
Glu	Lys	Tyr	Asp	Asp	Ile	Pro	Val		Glu	Ala	Thr	Gly	Asn	Asn	Cys
			485							490					495
Pro	His	Ile	Glu	Ser	Phe	Ser	Asp	Val	Glu	Met	Gly	Glu	Ile	Ile	Met
			500					505					510		
Gly	Asn	Ile	Glu	Leu	Thr	Arg	Tyr	Thr	Arg	Pro	Thr	Pro	Val	Gln	Lys
		515					520					525			
His	Ala	Ile	Pro	Ile	Ile	Lys	Glu	Lys	Arg	Lys	Tyr	Asp	Asp	Ile	Pro
	530					535					540				
Val	Glu	Ala	Thr	Gly	Asn	Asn	Cys	Pro	Pro	His	Ile	Glu	Ser	Phe	Ser
	545				550					555					560
Asp	Val	Glu	Met	Gly	Glu	Ile	Ile	Met	Gly	Asn	Ile	Glu	Leu	Thr	Arg
				565					570						575
Tyr	Thr	Arg	Pro	Thr	Pro	Val	Gln	Lys	His	Ala	Ile	Pro	Ile	Ile	Lys
			580					585					590		
Glu	Lys	Arg	Asp	Arg	Phe	Thr	Lys	Pro	Thr	Pro	Val	Gln	Lys	Tyr	Ser
		595					600					605			
Val	Pro	Ile	Val	Ala	Asn	Gly	Arg	Asp	Leu	Met	Ala	Cys	Ala	Gln	Thr
	610					615					620				
Gly	Ser	Gly	Lys	Thr	Gly	Gly	Phe	Leu	Phe	Pro	Val	Leu	Ser	Glu	Ser
	625				630					635					640
Phe	Lys	Thr	Gly	Pro	Ser	Pro	Gln	Pro	Glu	Ser	Gln	Gly	Ser	Asp	Leu
				645					650					655	
Met	Ala	Cys	Ala	Gln	Thr	Gly	Ser	Gly	Lys	Thr	Ala	Ala	Phe	Leu	Leu
			660					665					670		
Pro	Ile	Leu	Ser	Gln	Ile	Tyr	Ser	Asp	Gly	Pro	Gly	Glu	Ala	Leu	Arg
		675					680					685			
Ala	Met	Lys	Glu	Asn	Gly	Arg	Tyr	Gly	Arg	Arg	Lys	Gln	Tyr	Pro	Ile
	690					695					700				
Ser	Leu	Val	Leu	Ala	Pro	Thr	Arg	Leu	Met	Ala	Ala	Cys	Ala	Gln	Thr
	705				710					715				720	
Gly	Ser	Gly	Lys	Thr	Ala	Ala	Phe	Leu	Leu	Pro	Ile	Leu	Ser	Gln	Ile
				725					730					735	
Tyr	Thr	Asp	Gly	Pro	Gly	Glu	Ala	Leu	Arg	Ala	Met	Lys	Glu	Asn	Gly
			740					745					750		
Lys	Tyr	Gly	Arg	Arg	Lys	Gln	Tyr	Pro	Ile	Ser	Leu	Val	Leu	Ala	Pro
		755					760					765			
Thr	Arg	Glu	Phe	Tyr	Gln	Arg	Lys	Ala	Tyr	Pro	Thr	Ala	Val	Ile	Met
	770					775					780				
Ala	Pro	Thr	Arg	Glu	Leu	Ala	Thr	Gln	Ile	Phe	Asp	Glu	Ala	Lys	Lys
	785				790					795				800	
Glu	Phe	Thr	Tyr	Arg	Ser	Trp	Val	Lys	Ala	Cys	Val	Val	Tyr	Gly	Gly
				805					810					815	
Ser	Pro	Ile	Gly	Asn	Gln	Leu	Arg	Glu	Ile	Glu	Arg	Gly	Cys	Glu	Leu
			820					825					830		
Ala	Val	Gln	Ile	Tyr	Glu	Glu	Ala	Arg	Lys	Phe	Ser	Tyr	Arg	Ser	Arg
		835					840					845			

-continued

---

Val Arg Pro Cys Val Val Tyr Gly Gly Ala Asp Ile Gly Gln Gln Ile  
 850 855 860

Arg Asp Leu Glu Arg Gly Cys His Leu Leu Val Ala Thr Pro Gly Arg  
 865 870 875 880

Leu Val Asp Met Met Glu Arg Gly Leu Ala Val Gln Ile Tyr Glu Glu  
 885 890 895

Ala Arg Lys Phe Ser Tyr Arg Ser Arg Val Arg Pro Cys Val Val Tyr  
 900 905 910

Gly Gly Ala Asp Ile Gly Gln Gln Ile Arg Asp Leu Glu Arg Gly Cys  
 915 920 925

His Leu Leu Val Ala Thr Pro Gly Arg Leu Val Asp Met Met Glu Arg  
 930 935 940

Gly Lys Asp Leu Leu Val Ala Thr Pro Gly Arg Leu Asn Asp Leu Leu  
 945 950 955 960

Glu Arg Gly Lys Ile Ser Leu Ala Asn Val Lys Tyr Leu Val Leu Asp  
 965 970 975

Glu Ala Asp Arg Met Leu Asp Met Gly Phe Glu Pro Gln Ile Arg His  
 980 985 990

Ile Val Glu Asp Cys Asp Met Thr Pro Val Gly Glu Lys Ile Gly Leu  
 995 1000 1005

Asp Phe Cys Lys Tyr Leu Val Leu Asp Glu Ala Asp Arg Met Leu Asp  
 1010 1015 1020

Met Gly Phe Glu Pro Gln Ile Arg Arg Ile Val Glu Gln Asp Thr Met  
 1025 1030 1035 1040

Pro Pro Lys Gly Val Arg His Thr Met Met Phe Ser Ala Thr Phe Pro  
 1045 1050 1055

Lys Glu Ile Gln Met Leu Ile Gly Leu Asp Phe Cys Lys Tyr Leu Val  
 1060 1065 1070

Leu Asp Glu Ala Asp Arg Met Leu Asp Met Gly Phe Glu Pro Gln Ile  
 1075 1080 1085

Arg Arg Ile Val Glu Gln Asp Thr Met Pro Pro Lys Gly Val Arg His  
 1090 1095 1100

Thr Met Met Phe Ser Ala Thr Phe Pro Lys Glu Ile Gln Met Leu Ala  
 1105 1110 1115 1120

Arg Gln Thr Leu Met Phe Ser Ala Thr Phe Pro Ala Asp Ile Gln His  
 1125 1130 1135

Leu Ala Arg Asp Phe Leu Ser Asp Tyr Ile Phe Leu Ser Val Gly Arg  
 1140 1145 1150

Val Gly Ser Thr Ser Glu Asn Ile Thr Gln Lys Val Leu Tyr Val Glu  
 1155 1160 1165

Asn Gln Asp Lys Lys Ser Ala Leu Leu Asp Ala Arg Asp Phe Leu Asp  
 1170 1175 1180

Glu Tyr Ile Phe Leu Ala Val Gly Arg Val Gly Ser Thr Ser Glu Asn  
 1185 1190 1195 1200

Ile Thr Gln Lys Val Val Trp Val Glu Glu Ser Asp Lys Arg Ser Phe  
 1205 1210 1215

Leu Leu Asp Leu Leu Asn Ala Thr Gly Lys Asp Ser Leu Thr Leu Val  
 1220 1225 1230

Phe Val Glu Thr Arg Asp Phe Leu Asp Glu Tyr Ile Phe Leu Ala Val  
 1235 1240 1245

Gly Arg Val Gly Ser Thr Ser Glu Asn Ile Thr Gln Lys Val Val Trp  
 1250 1255 1260

-continued

---

Val	Glu	Glu	Ala	Asp	Lys	Arg	Ser	Phe	Leu	Leu	Asp	Leu	Leu	Asn	Ala
1265					1270					1275					1280
Thr	Gly	Lys	Asp	Ser	Leu	Ile	Leu	Val	Phe	Val	Glu	Thr	Lys	Leu	Leu
				1285					1290					1295	
Ser	Ala	Ser	Thr	Asp	Gly	Leu	Thr	Leu	Ile	Phe	Val	Glu	Thr	Lys	Arg
			1300					1305						1310	
Met	Ala	Asp	Gln	Leu	Thr	Asp	Phe	Leu	Ile	Met	Gln	Asn	Phe	Arg	Ala
		1315					1320						1325		
Thr	Ala	Ile	His	Gly	Asp	Arg	Thr	Gln	Ser	Glu	Arg	Glu	Arg	Ala	Leu
	1330					1335					1340				
Ala	Ala	Phe	Arg	Ser	Gly	Ala	Ala	Lys	Lys	Gly	Ala	Asp	Ser	Leu	Glu
1345					1350					1355					1360
Asp	Phe	Leu	Tyr	His	Glu	Gly	Tyr	Ala	Cys	Thr	Ser	Ile	His	Gly	Asp
				1365					1370					1375	
Arg	Ser	Gln	Arg	Asp	Arg	Glu	Glu	Ala	Leu	His	Gln	Phe	Arg	Ser	Gly
			1380						1385				1390		
Lys	Ser	Pro	Ile	Leu	Val	Ala	Thr	Ala	Val	Ala	Ala	Arg	Gly	Leu	Asp
		1395					1400						1405		
Ile	Ser	Lys	Gly	Ala	Asp	Ser	Leu	Glu	Asp	Phe	Leu	Tyr	His	Glu	Gly
	1410					1415					1420				
Tyr	Ala	Cys	Thr	Ser	Ile	His	Gly	Asp	Arg	Ser	Gln	Arg	Asp	Arg	Glu
1425					1430					1435					1440
Glu	Ala	Leu	His	Gln	Phe	Arg	Ser	Gly	Lys	Ser	Pro	Ile	Leu	Val	Ala
			1445						1450					1455	
Thr	Ala	Val	Ala	Ala	Arg	Gly	Leu	Asp	Ile	Ser	Asn	Thr	Leu	Leu	Val
		1460						1465						1470	
Ala	Thr	Ala	Val	Ala	Ala	Arg	Gly	Leu	Asp	Ile	Pro	Asn	Val	Thr	His
	1475						1480						1485		
Val	Ile	Asn	Tyr	Asp	Leu	Pro	Ser	Asp	Val	Asp	Asp	Tyr	Val	His	Arg
	1490					1495					1500				
Ile	Gly	Arg	Thr	Gly	Arg	Ala	Gly	Asn	Thr	Gly	Leu	Ala	Thr	Ala	Phe
1505					1510						1515				1520
Glu	Asn	Ser	Glu	Asn	Ser	Asn	Val	Lys	His	Val	Ile	Asn	Phe	Asp	Leu
				1525					1530					1535	
Pro	Ser	Asp	Ile	Glu	Glu	Tyr	Val	His	Arg	Ile	Gly	Arg	Thr	Gly	Arg
		1540						1545						1550	
Val	Gly	Asn	Leu	Gly	Leu	Ala	Thr	Ser	Phe	Phe	Asn	Glu	Arg	Asn	Ile
	1555						1560					1565			
Asn	Ile	Thr	Lys	Asp	Leu	Leu	Asp	Leu	Leu	Val	Glu	Ala	Lys	Gln	Glu
	1570					1575						1580			
Val	Lys	His	Val	Ile	Asn	Phe	Asp	Leu	Pro	Ser	Asp	Ile	Glu	Glu	Tyr
1585					1590					1595					1600
Val	His	Arg	Ile	Gly	Arg	Thr	Gly	Arg	Val	Gly	Asn	Leu	Gly	Leu	Ala
			1605						1610					1615	
Thr	Ser	Phe	Phe	Asn	Glu	Arg	Asn	Ile	Asn	Ile	Thr	Lys	Asp	Leu	Leu
			1620					1625						1630	
Asp	Leu	Leu	Val	Glu	Ala	Lys	Gln	Glu	Val	Asn	Ile	Val	Lys	Gly	Leu
	1635						1640						1645		
His	Glu	Ile	Leu	Thr	Glu	Ala	Asn	Gln	Glu	Val	Pro	Ser	Phe	Leu	Lys
	1650					1655						1660			
Asp	Ala	Met	Met	Ser	Ala	Pro	Gly	Ser	Arg	Ser	Asn	Ser	Arg	Arg	Gly
1665					1670					1675					1680
Gly	Phe	Gly	Arg	Asn	Asn	Asn	Arg	Asp	Tyr	Arg	Lys	Ala	Gly	Gly	Ala

